Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s strong position in the competitive landscape.

ALNY stock is testing its 52-week high. Check the latest price here.

Alnylam Pharmaceuticals stock is surging on Thursday after the company reported upbeat second-quarter earnings and 2025 guidance.

The company reported a second-quarter 2025 adjusted earnings of 32 cents, down from 56 cents a year ago. Analysts estimated a loss of 79 cents.

The company reported quarterly sales of $773.69 million, up 17% year over year, beating the consensus of $638.55 million.

Alnylam Pharmaceuticals achieved global net product revenues for Amvuttra and Onpattro for the second quarter ...